Interventions for mycosis fungoides

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

“…Consequently, although there are published treatment guidelines, [9][10][11] management approaches vary considerably for patients requiring systemic therapy. Moreover, because of the relative rarity of the disease, consensus guidelines are based on limited evidence, with no comparative studies across treatments, 12 and rather are shaped by the experience of leading clinicians. 13 For patients with early-stage disease, treatment generally begins with skin-directed therapies (SDT) such as psoralen plus UVA radiation (PUVA), narrowband UVB (nbUVB) radiation, topical corticosteroids, and sometimes topical chemotherapies.…”

Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant

“…Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphoma (CTCL), characterized as a chronic, malignant, and insidious course condition, initially affecting the skin . Pruritus is a highly limiting symptom in CTCL patients.…”

Psoralen with ultraviolet A‐induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1–STAT1 pathway

“…PUVA is a commonly used first‐line treatment for CTCL but its mechanism of action is not well understood. It is believed that PUVA exerts an antiproliferative and pro‐apoptotic activity through the formation of interstrand cross‐links and possible DNA monoadducts mediated by photoactivated psoralen .…”